Advertisement

Topics

Evotec Announces Strategic Investment in Facio Therapies to Support Development of Novel FSHD Therapy

01:52 EDT 20 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Evotec to participate in Facio Therapies' 2017 funding round alongside members of the FSHD community (totaL volume: EUR 4.8 m) Evotec expands its efforts in using patient-derived disease models to ide...

Other Sources for this Article

Evotec AG:
Gabriele Hansen, +49.(0)40.56081-255
VP Corporate Communications & Investor Relations
gabriele.hansen@evotec.com

NEXT ARTICLE

More From BioPortfolio on "Evotec Announces Strategic Investment in Facio Therapies to Support Development of Novel FSHD Therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Muscular Dystrophy
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...